Study: Drug, Chemo Combo Double Survival In Metastatic Lung Cancer | Latest News RSS feed

Study: Drug, Chemo Combo Double Survival In Metastatic Lung Cancer - Latest News

Pfizer's Drug Combo Betters Survival in Kidney Cancer Study

Pfizer, Inc. PFE announced that a combination of its cancer drugs, Bavencio and Inlyta, significantly improved progression-free-survival ... from the study showed that treatment with the ... read more

Priority Review in NSCLC, Label Update in CLL, Delayed FDA Decision in Lung Cancer, and More

In renal cell carcinoma, phase III results of the JAVELIN Renal 101 study showed that the combination of avelumab with axitinib significantly improved progression-free survival ... treatment of patien... read more

Pharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus

This week Merck’s (MRK - Free Report) PD-L1 inhibitor, Keytruda was in the limelight as it gained EU approval as a combination therapy for the first-line treatment of advanced lung ... s Drug Combo Be... read more

Looking for another news?

Prognostic Value of Low Tumor Burden in Patients With Melanoma

BRAF and MEK inhibitors are usually used in combination. Prolonged survival and improved responses to BRAF and MEK inhibitors have been demonstrated in patients with a smaller metastatic ... lung canc... read more

Merck's Keytruda Combo Gets Nod for Lung Cancer in Europe

The drug ... 189 study, which demonstrated superiority of Keytruda combination regimen in improving overall survival (“OS”) and progression free survival (“PFS”) over chemotherapy. read more

Your Cancer Highlight: Merck Tightening Its Grips On Front-Line Lung Cancer

Adding insult to injury, MRK's analogous study, KEYNOTE-024, DID demonstrate a survival ... indications in lung cancer: First-line, PD-L1 ≥1%, given alone In combination with chemotherapy ... read more

A young mother had a 'perfect' life. Then came the deadly cancer diagnosis

Once a disease where the primary risk factor was old age, the study found people born in 1990 have double ... had metastatic colon cancer, the doctor said. It was the only explanation for the liver ma... read more

Innovent Presents Clinical Data of Anti-PD-1 Antibody Sintilimab as the First-line Treatment for Patients with NSCLC at Annua...

The study shows evidence ... studies in the field of lung cancer. We hope these clinical trials in combination with sintilimab will lead to more effective treatment methods for cancer patients, giving ... read more

Frontline Pembrolizumab Combo Approved in Europe for Nonsquamous NSCLC

The European Commission has approved frontline pembrolizumab (Keytruda) for use in combination ... for the treatment of lung cancer,” added Perlmutter. The double-blind phase III KEYNOTE-189 study acc... read more

Researchers Get Funding Boost for Deadly Pancreatic Cancer

Pancreatic cancer has the worst survival rate of any major cancer but a team ... Altomare and Phanstiel are creating a combination treatment of two inhibitor drugs. The first blocks the “factory” insi... read more

New immune-stimulating drug, with chemo, shrinks pancreas tumors

Since surgery currently provides the best chance for survival of pancreatic cancer ... was nearly double the rate for people treated with chemotherapy alone. The trial results also concluded that the ... read more

First Patient Dosed in a Phase III Trial of Anti-PD-1 Antibody as First-line Treatment for Patients with Non-Squamous Non-Sma...

ORIENT-11 is a randomized, double-blinded, multicenter, phase III study ... chemotherapy as first-line treatment to advanced or recurrent non-squamous non-small cell lung cancer (ns-NSCLC) in China. P... read more

FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us